UBS Downgrades Biohaven on Pipeline Setbacks
UBS cuts Biohaven to Neutral from Buy, lowering the price target to $11 due to multiple R&D and regulatory setbacks and rising competition in its Kv7 program.
/ 3 items
#BHVN↓
FDA Rejects Biohaven's Troriluzole for Rare Neurological Disease, Company Slashes R&D Budget
FDA denies Biohaven's troriluzole approval for spinocerebellar ataxia citing real-world evidence concerns. Company cuts R&D spending 60% and refocuses on three key late-stage programs.
FDA Feedback Rocks uniQure: Gene Therapy for Huntington’s Disease Delayed
UniQure's stock plummeted after the FDA unexpectedly decided that the current clinical trial data for its promising Huntington's disease therapy, AMT-130, is not adequate for immediate marketing application (BLA).